Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Develo** novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
[HTML][HTML] DNA damage response in cancer therapy and resistance: challenges and opportunities
Resistance to chemo-and radiotherapy is a common event among cancer patients and a
reason why new cancer therapies and therapeutic strategies need to be in continuous …
reason why new cancer therapies and therapeutic strategies need to be in continuous …
[HTML][HTML] Vorinostat (SAHA) and breast cancer: an overview
A Wawruszak, L Borkiewicz, E Okon, W Kukula-Koch… - Cancers, 2021 - mdpi.com
Simple Summary Breast cancer (BC) is the most frequent malignancy diagnosed in 2020
worldwide. Despite significant advances in BC therapy, its pathogenesis is still not fully …
worldwide. Despite significant advances in BC therapy, its pathogenesis is still not fully …
New approaches in breast cancer therapy through green nanotechnology and nano-ayurvedic medicine–pre-clinical and pilot human clinical investigations
M Khoobchandani, KK Katti… - International journal …, 2020 - Taylor & Francis
Purpose The overarching objective of this investigation was to investigate the intervention of
green nanotechnology to transform the ancient holistic Ayurvedic medicine scientifically …
green nanotechnology to transform the ancient holistic Ayurvedic medicine scientifically …
[HTML][HTML] PARP1: Structural insights and pharmacological targets for inhibition
Abstract Poly (ADP-ribose) polymerase 1 (PARP1, also known as ADPRT1) is a
multifunctional human ADP-ribosyltransferase. It plays a role in multiple DNA repair …
multifunctional human ADP-ribosyltransferase. It plays a role in multiple DNA repair …
Platinum-based systematic therapy in triple-negative breast cancer
Y Zhu, Y Hu, C Tang, X Guan, W Zhang - Biochimica et Biophysica Acta …, 2022 - Elsevier
Due to the lack of definitive hormone receptors, triple negative breast cancer (TNBC)
patients receive little clinical benefit from endocrine or molecular targeted therapies, leading …
patients receive little clinical benefit from endocrine or molecular targeted therapies, leading …
Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer
B Lian, X Chen, K Shen - Frontiers in Immunology, 2023 - frontiersin.org
Breast cancer is one of the common malignancies with poor prognosis worldwide. The
treatment of breast cancer patients includes surgery, radiation, hormone therapy …
treatment of breast cancer patients includes surgery, radiation, hormone therapy …
[HTML][HTML] Proteins from the DNA damage response: Regulation, dysfunction, and anticancer strategies
Simple Summary Cells respond to genotoxic stress through complex protein pathways
called DNA damage response (DDR). These mechanisms ensure the preservation of …
called DNA damage response (DDR). These mechanisms ensure the preservation of …
Exploring the potential of metallodrugs as chemotherapeutics for triple negative breast cancer
This review focuses on studies of coordination and organometallic compounds as potential
chemotherapeutics against triple negative breast cancer (TNBC) which has one of the …
chemotherapeutics against triple negative breast cancer (TNBC) which has one of the …
Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
X Peng, W Pan, F Jiang, W Chen, Z Qi, W Peng… - Pharmacological …, 2022 - Elsevier
Poly ADP-ribose polymerase (PARP) plays a critical role in many cellular processes such as
DNA damage repair, gene transcription and cell apoptosis. Therefore, targeting PARP …
DNA damage repair, gene transcription and cell apoptosis. Therefore, targeting PARP …